Effects of newly developed chemotherapy regimens, comorbidities, chemotherapy-related toxicities on the changing patterns of the leading causes of death in elderly patients with colorectal cancer

Annals of Oncology

Volumn 25, Issue 6, 2014, Pages 1234-1242

  Tong, L ^a,b   Ahn, C ^b   Symanski, E ^a   Lai, D ^a   Du, Xianglin L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cause specific death; Chemotherapy related toxicity; Colorectal cancer; Comorbidity; Newly developed chemotherapy regimens

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; IRINOTECAN; OXALIPLATIN;

ADVERSE DRUG REACTION; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COLITIS; COLORECTAL CANCER; COMORBIDITY; DIARRHEA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; STOMATITIS; THROMBOCYTOPENIA; VERY ELDERLY; CANCER REGISTRY; COLORECTAL NEOPLASMS; MORTALITY; PROPORTIONAL HAZARDS MODEL; TRENDS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAUSE OF DEATH; COHORT STUDIES; COLORECTAL NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEER PROGRAM;

EID: 84903890185     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu131     Document Type: Article

References (40)

1. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104-117.
2. Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000; 355(9215): 1588-1596.
3. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27(19): 3109-3116.
4. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005; 23(13): 3112-3124.
5. Aparicio T, Navazesh A, Boutron I et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol 2009; 71(3): 249-257.
6. SEER Stat Fact Sheets: colon and rectum cancer. http://seer.cancer.gov/statfacts/html/colorect.html (11 April 2014, date last accessed).
7. Lee L, Cheung WY, Atkinson E et al. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol 2011; 29(1): 106-117.
8. Papamichael D, Audisio R, Horiot JC et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009; 20(1): 5-16.
9. Audisio RA, Papamichael D. Treatment of colorectal cancer in older patients. Nat Rev Gastroenterol Hepatol 2012; 9(12): 716-725.
10. Bakogeorgos M, Mountzios G, Kotsantis G et al. Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly patients with metastatic colorectal cancer: a single institution comparative study. J BUON 2013; 18(3): 629-634.
11. Rueth NM, Parsons HM, Habermann EB et al. The long-term impact of surgical complications after resection of stage I nonsmall cell lung cancer: a populationbased survival analysis. Ann Surg 2011; 254(2): 368-374.
12. Abraham A, Al-Refaie WB, Parsons HM et al. Disparities in pancreas cancer care. Ann Surg Oncol 2013; 20(6): 2078-2087.
13. White A, Vernon SW, Franzini L et al. Racial disparities in colorectal cancer survival: to what extent are racial disparities explained by differences in treatment, tumor characteristics, or hospital characteristics? Cancer 2010; 116(19): 4622-4631.
14. Wright FC, Law CH, Berry S et al. Clinically important aspects of lymph node assessment in colon cancer. J Surg Oncol 2009; 99(4): 248-255.
15. Sobin LH, Greene FL. TNM classification: clarification of number of regional lymph nodes for pNo. Cancer 2001; 92(2): 452.
16. Cancer advances in focus: colorectal cancer. http://www.cancer.gov/cancertopics/factsheet/cancer-advances-in-focus/colorectal (11 April 2014, date last accessed).
17. ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification, 6th edition.
18. American Medical Association: Physician Current Procedural Terminology: CPT 94. Chicago, IL: American Medical Association 1993.
19. Health Care Financing Administration: HCFA Common Procedure Coding System (HCPCS): National Level II Medicare Codes. Losangeles, CA: Practice Management Information Corporation 1994.
20. Cen P, Liu C, Du XL. Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Ann Oncol 2012; 23(6): 1503-1511.
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45(6): 613-619.
22. Charlson Comorbidity Index. http://appliedresearch.cancer.gov/seermedicare/program/comorbidity.html (11 April 2014, date last accessed).
23. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373-383.
24. Parsons HM, Tuttle TM, Kuntz KM et al. Association between lymph node evaluation for colon cancer and node positivity over the past 20 years. JAMA 2011; 306(10): 1089-1097.
25. Parsons HM, Begun JW, Kuntz KM et al. Lymph node evaluation for colon cancer in an era of quality guidelines: who improves? J Oncol Pract 2013; 9(4): e164-e171.
26. Leo S, Accettura C, Gnoni A et al. Systemic treatment of gastrointestinal cancer in elderly patients. J Gastrointest Cancer 2013; 44(1): 22-32.
27. Pentheroudakis G, Fountzilas G, Kalofonos HP et al. Palliative chemotherapy in elderly patients with common metastatic malignancies: a Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol 2008; 66(3): 237-247.
28. Hung A, Mullins CD. Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. Oncologist 2013; 18(1): 54-63.
29. Lemmens VE, Janssen-Heijnen ML, Verheij CD et al. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg 2005; 92(5): 615-623.
30. Remington PL, Brownson RC. Fifty years of progress in chronic disease epidemiology and control. MMWR Surveill Summ 2011; 60(Suppl 4): 70-77.
31. Ford ES, Ajani UA, Croft JB et al. Explaining the decrease in U. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356(23): 2388-2398.
32. Wijeysundera HC, Machado M, Farahati F et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 2010; 303(18): 1841-1847.
33. Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health 2011; 32: 5-22.
34. O'Flaherty M, Buchan I, Capewell S. Contributions of treatment and lifestyle to declining CVD mortality: why have CVD mortality rates declined so much since the 1960s? Heart 2013; 99(3): 159-162.
35. Myer PA, Mannalithara A, Singh G et al. Proximal and distal colorectal cancer resection rates in the United States since widespread screening by colonoscopy. Gastroenterology 2012; 143(5): 1227-1236.
36. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94(13): 981-990.
37. NCI. Cancer progress report: early detection of breast cancer. http://progressreport.cancer.gov/summary-tables_female.asp (11 April 2014, date last accessed).
38. SEER: quality improvement process. http://seer.cancer.gov/qi/process.html (11 April 2014, date last accessed).
39. Ambs A, Warren JL, Bellizzi KM et al. Overview of the SEER-Medicare Health Outcomes Survey linked dataset. Health Care Financ Rev 2008; 29(4): 5-21.
40. Surveillance E, End Results Program. SEER cause-specific death classification. http://seercancergov/causespecific/. 2008.